US 12,421,185 B2
Compositions and methods for treating cancer
Michael Freeman, West Hollywood, CA (US); Mirja Rotinen, Beverly Hills, CA (US); Ramachandran Murali, Beverly Hills, CA (US); and Sungyong You, Los Angeles, CA (US)
Assigned to CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Filed by Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed on Jan. 8, 2021, as Appl. No. 17/145,152.
Application 17/145,152 is a continuation of application No. 16/307,702, granted, now 10,927,070, previously published as PCT/US2017/034768, filed on May 26, 2017.
Claims priority of provisional application 62/421,733, filed on Nov. 14, 2016.
Claims priority of provisional application 62/348,013, filed on Jun. 9, 2016.
Prior Publication US 2021/0163403 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 237/08 (2006.01); A61K 31/165 (2006.01); A61K 31/397 (2006.01); A61K 31/40 (2006.01); A61K 31/416 (2006.01); A61K 31/4164 (2006.01); A61K 31/417 (2006.01); A61K 31/445 (2006.01); A61K 31/45 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07C 233/31 (2006.01); C07C 237/22 (2006.01); C07C 259/06 (2006.01); C07D 205/04 (2006.01); C07D 207/09 (2006.01); C07D 207/16 (2006.01); C07D 211/60 (2006.01); C07D 211/76 (2006.01); C07D 211/78 (2006.01); C07D 231/56 (2006.01); C07D 233/64 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01)
CPC C07C 237/08 (2013.01) [A61K 31/165 (2013.01); A61K 31/397 (2013.01); A61K 31/40 (2013.01); A61K 31/416 (2013.01); A61K 31/4164 (2013.01); A61K 31/417 (2013.01); A61K 31/445 (2013.01); A61K 31/45 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07C 233/31 (2013.01); C07C 237/22 (2013.01); C07C 259/06 (2013.01); C07D 205/04 (2013.01); C07D 207/09 (2013.01); C07D 207/16 (2013.01); C07D 211/60 (2013.01); C07D 211/76 (2013.01); C07D 211/78 (2013.01); C07D 231/56 (2013.01); C07D 233/64 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6886 (2013.01); C07B 2200/07 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 14 Claims
 
1. A compound represented by Formula IA:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein
Y is heteroaryl, which can be optionally substituted; and
n is 1 or 2; or
Y is —CH(NH2)CH2OH, —CH2CH2NHC(O)CH3, —CH2C(O)NHOH, —C(O)CH(NH2)CH2OH, —NHC(O)CH(NH2)CH2OH, piperidinecarboxamide, piperidone, or N-hydroxybenzamide; and
n is 1, 2, or 3.